02.16.10
Albemarle Corp. has entered a partnership with PharmaCore to provide manufacturing capabilities for customers with projects that require high volume capacity. This alliance allows PharmaCore to offer its customers long term, higher volume capacity for their pharmaceutical projects.Albemarle has custom manufacturing capabilities in South Haven, MI, Tyrone, PA, and Orangeburg, SC, providing APIs and advanced pharmaceutical intermediate production in a broad range of scale and chemistries.
"We are happy that PharmaCore chose Albemarle's custom manufacturing business unit, Fine Chemistry Services (FCS), to expand their expertise as a custom synthesis provider for their customers," said Steve LeVan, Albemarle's vice president of FCS. "I am confident that PharmaCore's valued customers will benefit from our premier service and production capabilities and look forward to partnering with each of them to bring their products to market quickly and effectively."
"Our customers already benefit from PharmaCore's med-chem services through current cGMP pilot plant capabilities.This new partnership with Albemarle will complete the process," said Brian Swierenga, PharmaCore's vice president of GMP operations. "We have formed long business relationships with many of our customers, synthesizing first batches for toxicology continuing through lab process development and ultimately providing cGMP material for clinical trials.This new Albemarle partnership offers an opportunity to transfer that learned technology to full-scale manufacturing."
"We are happy that PharmaCore chose Albemarle's custom manufacturing business unit, Fine Chemistry Services (FCS), to expand their expertise as a custom synthesis provider for their customers," said Steve LeVan, Albemarle's vice president of FCS. "I am confident that PharmaCore's valued customers will benefit from our premier service and production capabilities and look forward to partnering with each of them to bring their products to market quickly and effectively."
"Our customers already benefit from PharmaCore's med-chem services through current cGMP pilot plant capabilities.This new partnership with Albemarle will complete the process," said Brian Swierenga, PharmaCore's vice president of GMP operations. "We have formed long business relationships with many of our customers, synthesizing first batches for toxicology continuing through lab process development and ultimately providing cGMP material for clinical trials.This new Albemarle partnership offers an opportunity to transfer that learned technology to full-scale manufacturing."
